Aligos Therapeutics
1 Corporate Dr.
2nd Floor
South San Francisco
CA
94080
United States
Tel: 614-580-1758
Email: info@aligos.com
134 articles about Aligos Therapeutics
-
Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021
10/28/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s third quarter 2021 financial results on Thursday, November 4, 2021 after the close of U.S. financial markets.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting® 2021
10/14/2021
Aligos Therapeutics, Inc. today announced upcoming poster presentations highlighting data relating to its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) clinical programs at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12 - 15, 2021.
-
Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
10/11/2021
Aligos Therapeutics, Inc. today announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-020572-401 (NCT05001022).
-
Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
9/20/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Cantor Virtual Global Healthcare Conference.
-
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
8/5/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter, June 30, 2021.
-
Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
7/29/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s second quarter 2021 financial results on Thursday, August 5, 2021 after the close of U.S. financial markets.
-
Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
7/1/2021
Aligos Therapeutics, Inc. announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share.
-
Aligos Therapeutics Announces Proposed Public Offering of Common Stock
6/28/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock
-
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133
6/21/2021
- First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients -Presentations include nonclinical data from 3 other CHB programs.
-
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
6/14/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will present five abstracts highlighting data from the company’s chronic hepatitis B (CHB) therapeutic programs
-
Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference
6/10/2021
Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, announced that a poster describing data from the ongoing Study ALG-000184-201 will be presented at the HBV-TAG 2021 Conference, taking place virtually June 11-12, 2021.
-
Aligos Therapeutics to Present at the Jefferies Virtual Healthcare Conference - May 20, 2021
5/20/2021
Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, announced that Lawrence Blatt, Ph.D., MBA, CEO of Aligos, will present at the Jefferies Virtual Healthcare Conference being held June 1- 4, 2021.
-
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2021 Financial ResultsAdvancement of Aligos’ drug candidates continues to be on track
5/10/2021
Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported recent business progress and financial results for the first quarter March 31, 2021.
-
Aligos Therapeutics to Announce First Quarter 2021 Results May 10, 2021
5/5/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s first quarter 2021 financial results on Monday, May 10, 2021 after the close of the financial markets
-
Aligos Therapeutics Appoints James Scopa, J.D., MBA, to its Board of Directors
4/27/2021
Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, announced that the company has appointed James Scopa, J.D., MBA, to the Company’s board of directors.
-
Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184
4/14/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has started dosing in the first cohort of chronic hepatitis B (CHB) patients in the ongoing ALG-000184-201 study (NCT04536337).
-
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
3/23/2021
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced its financial results for the fourth quarter and full year 2020 and provided an overview of recent business highlights.
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.